Product Description
Asunaprevir is an orally bioavailable inhibitor of the nonstructural protein 3 (NS3), with potential activity against hepatitis C virus (HCV). (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Asunaprevir)
Mechanisms of Action: HCV-NS3/4A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Canada | Chile | Colombia | Japan | Korea | New Zealand | Peru | Russia | Taiwan | Turkey
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Asunaprevir](https://pryzm-maps.s3.us-west-2.amazonaws.com/12current_maps.png)
Countries in Clinic: China, Unknown Location
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Hepatitis C, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20132226 | P3 |
Active, not recruiting |
Hepatitis C, Chronic |
None |
|
CTR20132850 | P3 |
Active, not recruiting |
Hepatitis C, Chronic |
None |